Transcription Factor CP2 (TFCP2/LSF) has emerged as a crucial oncogenic driver, particularly in hepatocellular carcinoma (HCC) and other aggressive solid tumors. As an intracellular transcription factor historically deemed "undruggable," modern drug discovery is leveraging innovative modalities including small-molecule protein-protein interaction (PPI) inhibitors, PROTACs, and RNA therapeutics to target the TFCP2-YAP1 signaling axis.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TFCP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TFCP2 Recombinant Protein (Full-Length & DNA-binding Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. Ideal for EMSA and FP assays. |
View TFCP2 Products |
| Gene Delivery | TFCP2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and luciferase reporter assays. |
View TFCP2 Products |
| Benchmark Ab | Anti-TFCP2 Recombinant Antibody High-affinity positive control for Western Blot, ChIP, and IP assays. |
View TFCP2 Products |
| Validator | TFCP2 siRNA Set Sequence-verified knockdown pool for target specificity validation. |
View TFCP2 Products |
| Related Target A | YAP1 (Yes-Associated Protein 1) Synergistic partner; TFCP2 complexes with YAP1 to accelerate oncogenic transcription. |
View YAP1 Products |
| Related Target B | TFCP2L1 (Transcription Factor CP2 Like 1) Subfamily homolog; critical for off-target selectivity screening. |
View TFCP2L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DNA-Binding Inhibition Screening (EMSA/FP) | Recombinant TFCP2 proteins are sequence-verified and purified under native conditions to preserve DNA-binding domain conformation. |
| Subfamily Homolog Selectivity Screening | Complete target panel including TFCP2L1 and UBP1 proteins strictly verified by mass spectrometry. |
| Lack of Validated Positive Controls | Sequence-defined recombinant benchmark antibodies available for robust assay baselining. |
| Off-Target Phenotypic Effects | Validated siRNA knockdown sets included for rigorous genetic rescue and specificity checks. |
Live TFCP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TFCP2 therapeutics is intensifying, with major players shifting focus from traditional systemic therapies to targeted transcription factor disruption. As first-generation small-molecule inhibitors (such as FQI1 derivatives) demonstrate preclinical efficacy in disrupting the TFCP2-DNA interface, the next wave of R&D is targeting the TFCP2-YAP1 protein-protein interaction and utilizing targeted protein degradation (PROTACs) to overcome drug resistance in sorafenib-refractory HCC.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic/Biotech Consortiums | Hepatocellular Carcinoma, Colorectal Cancer | In vitro binding assays (Need high-purity, natively folded TFCP2 recombinant protein) |
| PROTAC / Degraders | Targeted Degradation Startups | Advanced Solid Tumors, Drug-Resistant HCC | Ubiquitination & degradation validation (Need Lentivirus for stable reporter cell lines) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Metastatic Breast Cancer, Melanoma | Target knockdown verification (Need sequence-verified TFCP2 siRNA sets) |